Rivaroxaban for Treatment of Patients With Suspected or Confirmed Heparin-Induced Thrombocytopenia

Phase 3

Terminated

• Conditions: Heparin-induced Thrombocytopenia
• Interventions: Drug: Rivaroxaban

• Registration Number: NCT01598168
• Lead Sponsor: McMaster University

Brief Summary

Heparin is an anticoagulant (blood thinner) that is commonly used to treat patients with heart attacks and patients with blood clots in their legs or lungs (venous thrombosis). Some patients develop an allergic reaction to heparin, a condition called heparin-induced thrombocytopenia (HIT). HIT makes blood clot, which is the opposite of what heparin was designed to do. These blood clots can lead to heart attacks, strokes, limb amputations, and death. The objective of this 200 patient study is to determine if a new blood thinner called rivaroxaban (Xarelto) can be used to treat HIT. Rivaroxaban can be taken by mouth, does not require blood testing, and had a low risk of bleeding when it was used to treat blood clots in other clinical trials. If this study shows that rivaroxaban can be used to treat HIT, there will be two very important benefits. For patients with HIT, the benefit will be having a safe, and easy-to-use drug to protect them from developing further life or limb-threatening blood clots. For the Canadian health care system, the benefit will be having a drug that is much less expensive than the drugs currently used to treat HIT.

Detailed Description

Consecutive adult patients with an intermediate or high clinical probability for HIT (according to the clinical prediction rule called the "4T's Score) will receive rivaroxaban 15 mg bid while awaiting confirmation or exclusion of HIT by the local laboratory assay. Patients who are confirmed to have HIT by the local laboratory assay will continue to receive rivaroxaban 15 mg bid until their platelet count ≥ 150 or until end of study (Day 30). At the time of platelet count recovery (typically 4-7 days), they will be transitioned to a maintenance dose of rivaroxaban (20 mg od) for a maximum of 30 days.

Study Timeline

• Study First Submitted: 2012-05-11
• Study First Submitted QC: 2012-05-11
• Study First Posted: 2012-05-15
• Study Start: 2013-01
• Primary Completion: 2015-07
• Study Completion: 2015-07
• Status Verified: 2016-03
• Last Update Submitted: 2016-03-24
• Last Update Posted: 2016-03-25

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 22

Inclusion Criteria

• Adult patients with 4T's Score greater than or equal to 4.

Exclusion Criteria

• Require ongoing anticoagulant therapy for a mechanical heart valve.
• Severe renal insufficiency (CrCl<30 ml/min)
• Hepatic disease (including Child-Pugh B and C) associated with coagulopathy and a clinically relevant bleeding risk
• Inability to take oral medications.
• Ongoing requirement for systemic treatment with azole-antimycotics (except fluconazole) or HIV-protease inhibitors or strong CYP3A4 inducers
• Clinically significant active bleeding or lesions at increased risk for bleeding within the last 6 months
• Platelet count less than 80 and an ongoing need for antiplatelet therapy may be excluded at the discretion of the investigator
• Pregnant or a woman of child-bearing potential not using an adequate birth control method
• Hypersensitivity to rivaroxaban or to any ingredient in the formulation.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Rivaroxaban	Rivaroxaban	Rivaroxaban 15 mg bid until HIT excluded by local laboratory assay or platelets recovered. If HIT positive and platelets have recovered, patients will receive rivaroxaban 20 mg od until Day 30.

Primary Outcome Measures

Name	Time	Method
Incidence of new symptomatic venous and arterial thromboembolism in the study population.	30 days

Secondary Outcome Measures

Name	Time	Method
Incidence of symptomatic venous and arterial thromboembolism and major bleeding in patients while on-treatment with rivaroxaban.	30 days
Duration of time to platelet recovery in patients with Serotonin Release Assay (SRA) confirmed HIT	30 days
Incidence of venous and arterial thromboembolism in patients with SRA confirmed HIT who receive rivaroxaban.	30 days
Major bleeding in the entire study population and in patients with SRA confirmed HIT who receive rivaroxaban.	30 days
To collect data to prospectively validate a new clinical prediction rule for HIT	30 days

Trial Locations

Locations (1)

Hamilton Health Sciences - Juravinski Site; 🇨🇦 Hamilton, Ontario, Canada